Myriad Genetics, Inc.
Myriad Genetics, Inc. (MYGN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mygn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Myriad Genetics, Inc. (MYGN) measures how much investors pay for each dollar of the company's trailing earnings. MYGN's current PE ratio of N/A is calculated by dividing its stock price of $4.39 by its TTM earnings per share of -$4.27.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 12 fiscal years · Front-end computedMinQ1 · 25%20.0x
MedianQ3 · 75%439.2x
Max
At N/A, MYGN's current P/E is lower than in 0% of its annual fiscal year readings over the past 12 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Myriad Genetics, Inc.You MYGN | $415M | N/A | — | -$4.27 |
 AMN Healthcare Services, Inc. AMN | $1.2B | N/A | — | -$2.48 |
 CareDx, Inc CDNA | $1.1B | N/A | — | -$0.40 |
 Castle Biosciences, Inc. CSTL | $617M | N/A | — | -$0.83 |
 Ginkgo Bioworks Holdings, Inc. DNA | $527M | N/A | — | -$5.64 |
 DarioHealth Corp. DRIO | $54M | N/A | — | -$0.84 |
 Evolent Health, Inc. EVH | $547M | N/A | — | -$4.68 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.92 | — | |
2024-12-31 FY2024 | — | $-1.41 | — | |
2023-12-31 FY2023 | — | $-3.18 | — | |
2022-12-31 FY2022 | — | $-1.39 | — | |
2021-12-31 FY2021 | — | $-0.35 | — | |
2020-12-31 FY2020 | — | $-2.99 | — | |
2020-06-30 FY2020 | — | $-2.69 | — | |
2019-06-30 FY2019 | 439.24x | $0.06 | +2118.7% | |
2018-06-30 FY2018 | 19.80x | $1.89 | -75.5% | |
2017-06-30 FY2017 | 80.96x | $0.32 | +373.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Myriad Genetics, Inc. (MYGN) measures how much investors pay for each dollar of the company's trailing earnings. MYGN's current PE ratio of N/A is calculated by dividing its stock price of $4.39 by its TTM earnings per share of -$4.27.
Frequently asked questions
MYGN pe ratio · 6 questionsMYGN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.39 and TTM EPS of -$4.27. Data sourced from Financial Modeling Prep via MYGN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Myriad Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08